Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2004 5
2005 2
2006 4
2007 1
2008 3
2009 6
2010 3
2011 4
2012 5
2013 14
2014 8
2015 11
2016 15
2017 21
2018 21
2019 24
2020 28
2021 22
2022 26
2023 21
2024 14

Text availability

Article attribute

Article type

Publication date

Search Results

228 results

Results by year

Filters applied: . Clear all
Page 1
Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial.
Rha SY, Oh DY, Yañez P, Bai Y, Ryu MH, Lee J, Rivera F, Alves GV, Garrido M, Shiu KK, Fernández MG, Li J, Lowery MA, Çil T, Cruz FM, Qin S, Luo S, Pan H, Wainberg ZA, Yin L, Bordia S, Bhagia P, Wyrwicz LS; KEYNOTE-859 investigators. Rha SY, et al. Lancet Oncol. 2023 Nov;24(11):1181-1195. doi: 10.1016/S1470-2045(23)00515-6. Epub 2023 Oct 21. Lancet Oncol. 2023. PMID: 37875143 Clinical Trial.
Erratum.
Hu W, Lu Z, Meng F, Li X, Cong R, Ren T, Sharkey TD, Lu J. Hu W, et al. Among authors: lu j. New Phytol. 2021 Sep;231(6):2398. doi: 10.1111/nph.17472. Epub 2021 Aug 13. New Phytol. 2021. PMID: 34390258 Free article. No abstract available.
Efficacy and safety of a novel anti-HER2 therapeutic antibody RC48 in patients with HER2-overexpressing, locally advanced or metastatic gastric or gastroesophageal junction cancer: a single-arm phase II study.
Peng Z, Liu T, Wei J, Wang A, He Y, Yang L, Zhang X, Fan N, Luo S, Li Z, Gu K, Lu J, Xu J, Fan Q, Xu R, Zhang L, Li E, Sun Y, Yu G, Bai C, Liu Y, Zeng J, Ying J, Liang X, Xu N, Gao C, Shu Y, Ma D, Dai G, Li S, Deng T, Cui Y, Fang J, Ba Y, Shen L. Peng Z, et al. Among authors: lu j. Cancer Commun (Lond). 2021 Nov;41(11):1173-1182. doi: 10.1002/cac2.12214. Epub 2021 Oct 19. Cancer Commun (Lond). 2021. PMID: 34665942 Free PMC article. Clinical Trial.
First-line nivolumab plus chemotherapy vs chemotherapy in patients with advanced gastric, gastroesophageal junction and esophageal adenocarcinoma: CheckMate 649 Chinese subgroup analysis.
Liu T, Bai Y, Lin X, Li W, Wang J, Zhang X, Pan H, Bai C, Bai L, Cheng Y, Zhang J, Zhong H, Ba Y, Hu W, Xu R, Guo W, Qin S, Yang N, Lu J, Shitara K, Lei M, Li M, Bao N, Chen T, Shen L. Liu T, et al. Among authors: lu j. Int J Cancer. 2023 Feb 15;152(4):749-760. doi: 10.1002/ijc.34296. Epub 2022 Oct 31. Int J Cancer. 2023. PMID: 36121651 Free PMC article. Clinical Trial.
miR-449a: a potential therapeutic agent for cancer.
Yong-Ming H, Ai-Jun J, Xiao-Yue X, Jian-Wei L, Chen Y, Ye C. Yong-Ming H, et al. Anticancer Drugs. 2017 Nov;28(10):1067-1078. doi: 10.1097/CAD.0000000000000555. Anticancer Drugs. 2017. PMID: 29023247 Review.
Deep Ranking Exemplar-Based Dynamic Scene Deblurring.
Li Y, Pan J, Luo Y, Lu J. Li Y, et al. Among authors: lu j. IEEE Trans Image Process. 2022;31:2245-2256. doi: 10.1109/TIP.2022.3142518. Epub 2022 Mar 11. IEEE Trans Image Process. 2022. PMID: 35044913
Cross-Modal Prostate Cancer Segmentation via Self-Attention Distillation.
Zhang G, Shen X, Zhang YD, Luo Y, Luo J, Zhu D, Yang H, Wang W, Zhao B, Lu J. Zhang G, et al. Among authors: lu j. IEEE J Biomed Health Inform. 2022 Nov;26(11):5298-5309. doi: 10.1109/JBHI.2021.3127688. Epub 2022 Nov 10. IEEE J Biomed Health Inform. 2022. PMID: 34767517
Detecting subnetwork-level dynamic correlations.
Yan Y, Qiu S, Jin Z, Gong S, Bai Y, Lu J, Yu T. Yan Y, et al. Among authors: lu j. Bioinformatics. 2017 Jan 15;33(2):256-265. doi: 10.1093/bioinformatics/btw616. Epub 2016 Sep 25. Bioinformatics. 2017. PMID: 27667792 Free PMC article.
Pembrolizumab versus paclitaxel for previously treated advanced gastric or gastroesophageal junction cancer (KEYNOTE-063): A randomized, open-label, phase 3 trial in Asian patients.
Chung HC, Kang YK, Chen Z, Bai Y, Wan Ishak WZ, Shim BY, Park YL, Koo DH, Lu J, Xu J, Chon HJ, Bai LY, Zeng S, Yuan Y, Chen YY, Gu K, Zhong WY, Kuang S, Shih CS, Qin SK. Chung HC, et al. Among authors: lu j. Cancer. 2022 Mar 1;128(5):995-1003. doi: 10.1002/cncr.34019. Epub 2021 Dec 8. Cancer. 2022. PMID: 34878659 Free PMC article. Clinical Trial.
228 results